Assertio Posts Higher Q1 Sales, Profits; Lifts FY22 Adjusted EBITDA Outlook

  • Assertio Holdings Inc ASRT posted Q1 sales of $35.5 million, up 37% Y/Y, surpassing the consensus of $33.06 million.
  • The increase was primarily driven by higher net pricing on Indocin and the addition of Otrexup.
  • The gross profit margin was 88% or 344 basis points higher than the prior-year quarter due to a change in product mix and improved margins on Indocin.
  • Adjusted EBITDA increased from $15.7 million to $23.9 million.
  • The company posted an adjusted EPS of $0.38, compared to $0.27 a year ago and well ahead of the consensus of $0.09.
  • Guidance: Assertio reaffirmed FY22 sales of $126 million - $136 million, compared to the consensus of $131.71 million.
  • It expects adjusted EBITDA of $66 million - $74 million, higher than the previous guidance of $64 million - $72 million.
  • Price Action: ASRT shares are 18.6% at $2.23 during the market session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsPenny StocksGuidanceHealth CareMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!